Recombinant Mouse OGN Protein, N-His from ProteoGenix; catalogue ARO-P11105; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Mouse Osteoglycin (OGN) Protein is a type of recombinant protein that has been extensively studied for its role in bone development and regeneration. OGN is a small leucine-rich proteoglycan that is found in the extracellular matrix of various tissues, including bone, cartilage, and tendons. It is known to play a crucial role in regulating cell adhesion, proliferation, and differentiation, making it a promising candidate for various therapeutic applications.
Recombinant Mouse OGN Protein is a 28-kDa protein that is composed of 248 amino acids. It belongs to the small leucine-rich proteoglycan (SLRP) family and contains a leucine-rich repeat (LRR) domain, which is responsible for its interaction with other proteins and extracellular matrix components. The LRR domain is composed of 10–12 tandem repeats of 20–30 amino acids, with each repeat containing a conserved leucine residue. This unique structural feature allows OGN to interact with a variety of proteins and modulate their activities.
In addition to the LRR domain, OGN also contains a glycosaminoglycan (GAG) attachment site, which is responsible for its ability to bind to proteoglycans in the extracellular matrix. This GAG attachment site is important for OGN’s role in cell adhesion and signaling, as it allows it to interact with various cell surface receptors and regulate their activity.
Recombinant Mouse OGN Protein has been shown to have a wide range of activities in various tissues and cell types. One of its main functions is its role in regulating bone development and regeneration. OGN has been found to be highly expressed in the extracellular matrix of developing bones and plays a crucial role in the formation and mineralization of bone tissue. It has also been shown to promote the differentiation of mesenchymal stem cells into osteoblasts, the cells responsible for bone formation.
Moreover, OGN has been found to have anti-inflammatory properties, making it a potential therapeutic target for conditions such as osteoarthritis and rheumatoid arthritis. It has been shown to inhibit the production of inflammatory cytokines and enzymes, which are responsible for the breakdown of cartilage and joint damage in these conditions.
In addition to its role in bone and joint health, OGN has also been shown to have a role in wound healing and tissue repair. It has been found to promote the migration and proliferation of fibroblasts, the cells responsible for producing collagen and repairing damaged tissues. This makes OGN a potential candidate for the development of wound healing therapies.
The unique properties of Recombinant Mouse OGN Protein make it a promising candidate for various therapeutic applications. Its role in bone development and regeneration makes it a potential treatment for bone disorders such as osteoporosis and bone fractures. It can also be used in tissue engineering approaches for bone repair and regeneration.
Furthermore, OGN’s anti-inflammatory properties make it a potential therapeutic target for conditions such as osteoarthritis and rheumatoid arthritis. It can also be used in combination with other anti-inflammatory agents to enhance their effectiveness.
Moreover, OGN’s role in wound healing and tissue repair makes it a potential candidate for the development of wound healing therapies. It can be used in combination with growth factors and other molecules to promote tissue regeneration and accelerate wound healing.
In summary, Recombinant Mouse OGN Protein is a promising candidate for various therapeutic applications due to its unique structure and diverse range of activities. Its role in bone development and regeneration, anti-inflammatory properties, and potential for tissue repair make it a valuable protein
ProteoGenix catalogue number ARO-P11105. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 25.80 kDa; Fragment: Met91-Phe298; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
